Mass vaccination is a Phase 3 trial. This result is not surprising. Helsinki Declaration is clear. Immune related issues can take time to develop. The UK will very likely have seen these cases if vaccine linked. So we need to ask some questions....https://www.vg.no/nyheter/innenriks/i/wenlan/behandlende-lege-om-blodpropp-funn-ikke-sett-noe-i-denne-gaten-foer …
-
Deze collectie tonen
-
1. Which antibodies are they? What panels have they reacted to? Are they anticardiolipins that we know can follow vaccination?
1 antwoord 0 retweets 3 vind-ik-leuksDeze collectie tonen -
2. When will this data be published?
1 antwoord 0 retweets 3 vind-ik-leuksDeze collectie tonen -
3. The Oxford vaccine made use of a previously experimental vaccine vector. Are the antibodies specific to the empty vector? This CAN be demonstrated using patient sera. This would be a GAME CHANGER. If these anti-platelet antibodies are specific to the Oxford vector, whoa!!!
1 antwoord 1 retweet 3 vind-ik-leuksDeze collectie tonen
4. This is crucial. We need to know the source of these antibodies and we need to know their clinical significance. Immediately.
08:20 - 18 mrt. 2021
0 antwoorden
0 retweets
2 vind-ik-leuks
Het laden lijkt wat langer te duren.
Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.